Farmaceutický priemysel

This page is also available in:

  • Adopted on 27/04/2021 - Bureau decision date: 01/12/2020
    Referenčné dokumenty
    INT/926-EESC-2020-5886
    Civil Society Organisations - GR III
    Austria

    The Commission proposes a new pharmaceutical strategy for Europe. It is a patient-centred strategy that aims to ensure the quality and safety of medicines, while boosting the sector’s global competitiveness. The EU needs to make sure that patients have access to high-quality, effective and safe medicines. It will foster patient access to innovative and affordable medicines. It will support the competitiveness and innovative capacity of the EU’s pharmaceutical industry.

    EESC opinion: Pharmaceutical strategy
  • Adopted on 20/03/2020 - Bureau decision date: 20/03/2020
    Referenčné dokumenty
    ECO/515-EESC-2020-01536-00-01-PAC-TRA
    Civil Society Organisations - GR III
    Position Paper - Regulation on Coronavirus Response Investment Initiative
  • Adopted on 02/03/2020 - Bureau decision date: 20/03/2020
    Referenčné dokumenty
    ECO/516-EESC-2020-01-01-01535-00-01-pac-tra
    Workers - GR II
    EESC opinion: Financial aid for Member States and countries still negotiating the terms of their accession to the EU which are seriously affected by a major public health emergency
    Position paper - Financial assistance to Member States affected by a major public health emergency
  • Adopted on 23/04/2015
    Referenčné dokumenty
    CCMI/128-EESC
    Workers - GR II
    Italy
    Civil Society Organisations - GR III
    Germany

    Health and related sectors are a central aspect of human existence and thus attract particular attention of citizens. The sectors of biomedical engineering and the medical and care services industry – including research and development – are among the fastest growing industrial areas, in terms of turnover as well as employment. Under biomedical engineering we understand the bridging between methods of engineering and medicine and biology for diagnostic and therapeutic measures in healthcare – including, among others, biologics and biopharmaceuticals, pharmaceutical drugs, various types of devices for chemical or biological analysis or processing as well as the development of medical equipment and technology for cure, treatment and prevention of disease. The combination of research and development, engineering and industrial production, and medical and care services is particularly important.

     

    Presentation by Prof. Stefan N. Constantinescu
    Presentation by Andre Linnenbank, Secretary General of EAMBES
    Presentation by Manfred Bammer, MSc, MAS | Head of Biomedical Systems
    Presentation by Nicolas Gouze, General Secretary of ETP Nanomedicine
    Presentation by Prof. dr. ir. Pascal Verdonck
    Presentation by Ruxandra Draghia-Akli Director Health DG Research and Innovation European Commission
  • Adopted on 21/01/2015
    Referenčné dokumenty
    INT/762-EESC-2014-06070-00-01-AC-TRA
    Civil Society Organisations - GR III
    Germany
    Plenary session number
    504
    -
  • Adopted on 29/04/2014
    Referenčné dokumenty
    CCMI/119-EESC-2013-01-01-6794
    Employers - GR I
    Portugal
    Workers - GR II
    Italy

    Due to the increased need for cost-efficient procedures and the pressure on public expenditure, the European market for pharmaceutical products is less dynamic than in the past. This high-technology sector is faced with the following challenges: austerity measures introduced by European governments, rapid growth in the market and research in emerging economies, and migration of economic, research and development activities outside of Europe.

  • Adopted on 21/01/2014
    Referenčné dokumenty
    SOC/497-EESC-2013-01-01-6166
    Employers - GR I
    United Kingdom
    Plenary session number
    495
    -
  • Adopted on 16/10/2013
    Referenčné dokumenty
    INT/712-EESC-2013-5169
    Civil Society Organisations - GR III
    Germany
    Plenary session number
    493
    -
  • Adopted on 22/05/2013
    Referenčné dokumenty
    INT/694-EESC-2013-01-01-3335
    Plenary session number
    490
    -
  • Adopted on 14/02/2013
    Referenčné dokumenty
    INT/665-EESC-2012-01-01-2185
    Employers - GR I
    Slovenia
    Plenary session number
    487
    -
    Presentation by the EC, 26.09.2012